23. Novel Antifungal Agents, Formulations and Strategies
Thursday, October 8, 2015: 8:30 AM-10:00 AM
Room: 1--AB
Co-organized with the National Institute of Allergy and Infectious Diseases

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the emerging role of new drugs and new drug formulations in antifungal therapy in clinical practice
  • discuss the pharmacological characteristics of novel antifungal agents and formulations

Target Audience: Scientists, Researchers, Pharmacists, Microbiologists, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, HIV specialists, HIV clinicians, Epidemiologists, Clinicians, Academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Adult ID

Moderators:  Eleftherios Mylonakis, MD, PhD, FIDSA, Rhode Island Hospital and Michail Lionakis, MD, ScD, National Institutes of Health

8:30 AM
New Antifungal Compounds
Peter Pappas, MD
9:30 AM

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-148-L01-P


E. Mylonakis, T2 biosystems: Grant Investigator , Research grant
Astellas Pharma: Board Member and Grant Investigator , Consulting fee and Grant recipient
Boehringer Ingelheim: Grant Investigator , Research grant

M. Lionakis, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.